Help | Scores |Exit
Fragmin | Magnex | Solu Medrol
Amiloride Drug Name:  
A|B|C|D|E|F|G|H|I|K|L|M|N|O|P|Q|R|S|T|V|Z
Indications
Dosages
Interactions
Precautions
Contraindications
Adverse Reactions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions:

Benazepril

  • Adverse Effect: hyperkalemia
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Captopril

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Celecoxib

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Celecoxib and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Diclofenac Preps.

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering nonsteroidal antiinflammatory agents (NSAIDs) and potassium sparing diuretics concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Digoxin

  • Adverse Effect: decreased digoxin effectiveness  
  • Clinical Management: Monitor patients for reduced therapeutic effect of digoxin.

    Enalapril

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Flurbiprofen

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Flurbiprofen and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Ibuprofen

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Ibuprofen and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Ibuprofen Comb.

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Comb. Ibuprofen and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Indomethacin

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Indomethacin and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Ketoprofen

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Ketoprofen and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Ketorolac

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Ketorolac and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Lisinopril

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Lithium

  • Adverse Effect: increased lithium concentration and lithium toxicity (weakness, tremor, excessive thirst, confusion)  
  • Clinical Management: Monitor serum lithium levels within the first five to seven days of adding or discontinuing amiloride and periodically thereafter. Changes in the lithium dose may be required with concomitant amiloride therapy.

    Mefenamic Acid

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Mefenamic Acid and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Meloxicam

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Meloxicam and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels

    Metformin

  • Adverse Effect: an increased risk of lactic acidosis  
  • Clinical Management: In patients receiving metformin and Amiloride , closely monitor blood glucose concentrations. Metformin doses may need to be reduced.

    Nabumetone

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Nabumetone and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels

    Naproxen

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Naproxen and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Nimesulide

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Nimesulide and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Oxyphenbutazone

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Oxyphenbutazone and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Paracetamol

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Paracetamol and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Paracetamol Comb.

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Comb. Paracetamol and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Perindopril

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Phenacetin

  • Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Phenacetin and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Phenylbutazone

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Phenylbutazone and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Piroxicam

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Piroxicam and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.

    Quinidine

  • Adverse Effect: an increased risk of arrhythmias in patients with ventricular tachycardia  
  • Clinical Management: Patients receiving quinidine therapy should avoid the use of amiloride.

    Ramipril

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Tenoxicam

  • Adverse Effect: reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity  
  • Clinical Management: When administering Tenoxicam and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.
  • Acetaminophen
    Adenosine
    AlbuterolSulfate
    Allopurinol
    Alprostadil
    AmantadineHydrochloride
    AmikacinSulfate
    Aminophylline
    Amoxicillin
    AmoxicillinTrihydrate
    Amphotericin B
    Amphotericin B Cholesteryl Sulfate Complex
    Ampicillin
    Ampicillin Sodium
    Ascorbic Acid (Vitamin C)
    Aspirin
    Atropine Sulfate
    Azelastine Hydrochloride
    Aztreonam
    Abciximab
    Acenocoumarol
    Acarbose
    Acetazolamide
    Acetazolamide - Ocular
    Acyclovir
    Acyclovir - Ocular
    Acyclovir-AV
    Adapalene
    Adrenaline
    Adrenaline - Inh
    Adrenaline - resp
    Adrenochrome
    Albendazole
    Aldosterone
    Alendronate
    Alprazolam
    Amantadine-AV
    Amifostine
    Amikacin
    Amiloride
    Aminocaproic Acid
    Amiodarone
    Amitriptyline
    Amlodipine
    Amodiaquine
    Amoxapine
    Amrinone
    Analgin
    Aprotinin
    Ardeparin
    Arteether
    Artemether
    Artesunate
    Aspartame
    Astemizole
    Atenolol
    Atorvastatin
    Atracurium
    Auranofin ( Gold )
    Azatadine
    Azathioprine
    Azithromycin
     
    Disclaimer